top of page

CBP Seizes 5,000+ Peptide Shipments: Navigating CBP and FDA Issues as an Importer

  • Writer: clarkespositolaw
    clarkespositolaw
  • 1 day ago
  • 3 min read

In need of assistance? Schedule an intake meeting with our office.


A recent enforcement action by U.S. Customs and Border Protection (CBP) at the Port of Cincinnati highlights the types of issues that can quickly escalate into serious problems for importers. Between December 2025 and March 25, 2026, CBP officers intercepted over three hundred (300) shipments originating from China that were structured as “master cartons” containing smaller, pre-labeled packages destined for individual recipients in the United States. In total, the agency identified approximately five thousand (5,000) individual shipments of peptides, including compounds associated with GLP-1 weight loss drugs such as semaglutide, tirzepatide, and retatrutide.


While the headlines focus on the nature of the products, the more important takeaway for importers is how the shipments were handled from a compliance standpoint. According to CBP, the goods were mis-manifested and structured in a way that concealed their true contents. This type of mis-declaration, whether intentional or the result of poor oversight, can independently justify seizure, regardless of the underlying product. CBP treats these discrepancies seriously, particularly where shipments appear designed to avoid inspection or proper entry procedures.


In addition to customs-related concerns, the products at issue fall under the jurisdiction of the U.S. Food and Drug Administration (FDA), which regulates therapeutic peptides as drugs. This creates a layered enforcement environment where importers may face both CBP action and FDA admissibility issues at the same time. Even where an importer believes a product is being marketed as a research chemical or otherwise outside FDA oversight, the agency often takes a broader view, especially when products resemble known pharmaceutical compounds or are associated with health or weight loss uses.


Even if an importer is not directly involved in how goods are labeled, consolidated, or shipped, CBP will still hold the importer of record responsible for ensuring that entries are accurate and compliant. In practice, this means that issues originating with an overseas supplier, freight forwarder, or other intermediary can still be attributed to the importer. What may begin as a lack of visibility into how a shipment was handled can quickly result in a detention, seizure, or penalty action.


Importers dealing with a detention or seizure often face uncertainty about what steps to take and how to respond. Early decisions can have a meaningful impact on the outcome, particularly where statements or submissions are made without a full understanding of the regulatory framework. It is critical to assess whether the issue is limited to customs compliance or whether FDA requirements are also implicated, as this will shape the response strategy and available options.


How We Can Help


At Clark-Esposito Law Firm, P.C., we work with importers who encounter problems with CBP and FDA, including seizures, detentions, penalty actions, and other issues. We assist in evaluating the basis for enforcement, communicating with the agencies, and developing a strategy to respond effectively while minimizing risk. We also help importers identify what went wrong and implement practical steps to avoid similar issues in the future. If your shipment has been flagged or seized, addressing the situation early and strategically can make a significant difference in the outcome. Give our office a call today at (917) 546-6997 or schedule an intake meeting, we would be happy to speak with you.


Ready to Learn More About CBP, OFAC,

BIS, FWS, and FDA?


We have over one hundred videos in our educational library on our YouTube channel related to importing, exporting, US Customs, BIS, OFAC, FWS, FDA, NFTs, and so much more. Subscribe to our channel now to stay up to date on the latest on these topics!


Our law firm helps growing companies who import and export comply with government regulations. We love what we do and we take our oath of confidentiality over your matters very seriously. How much? Watch this video to learn about it. CLICK HERE 


 Wondering "why should you have an attorney on your side?" Click here to watch one of our attorneys, Susan Steinman, break down the critical benefits as to why you want to have one on your side - whether you hire us to help you or another law firm.


Have questions? We are determined to help you.

We listen carefully to clients to ensure our understanding of the legal issues at hand, their factual context, and any limitations that might impact a chosen strategy. Feel free to connect with us using the contact form at the bottom of the Home page or send us an email at contact@clarkespositolaw.com.  

 
 
 

Comments


How can we be of help?

New York Office:

211 E. 43rd Street, 7th Floor

New York, NY 10017

Connecticut Office:

9 Mott Ave., Suite 210

Norwalk,  CT 06850

917.546.6997

Stay Connected. Subscribe.

Thanks for subscribing!

  • YouTube
  • Instagram
  • LinkedIn
  • Facebook

Per The NY State Attorney Ethics Rules, See The Following Statement:

 

Attorney Advertising Disclaimer: The content of this website has been prepared by the Clark-Esposito Law Firm, P.C. for informational purposes only and should not be construed as legal advice. The material posted on this website is not intended to create, and receipt of it does not constitute, a lawyer-client relationship, and readers should not act upon it without seeking professional legal counsel. The Clark-Esposito Law Firm, P.C., did not produce and is not responsible for the content of off-site legal resources. The materials on this site may constitute advertising under various state ethics rules.

NYC, NYS, & PANYNJ M/WBE Certified Minority/Women Owned and Led Business

© 2025 by Clark-Esposito Law Firm, P.C.

bottom of page